Valneva Se Adr Stock Today
| VALN Stock | USD 4.37 0.06 1.39% |
Performance0 of 100
| Odds Of DistressOver 75
|
Valneva SE is selling at 4.37 as of the 17th of January 2025; that is 1.39% increase since the beginning of the trading day. The stock's open price was 4.31. Valneva SE has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of November 2024 and ending today, the 17th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of May 2021 | Category Healthcare | Classification Health Care |
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company was founded in 1998 and is headquartered in Saint-Herblain, France. Valneva Se is traded on NASDAQ Exchange in the United States.. The company has 81.2 M outstanding shares of which 15.89 K shares are at this time shorted by private and institutional investors with about 0.24 trading days to cover. More on Valneva SE ADR
Moving together with Valneva Stock
Moving against Valneva Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Valneva Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Thomas Lingelbach | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | Showing 3 out of 5 themes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Valora Holding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Management, Computers, IT, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsValneva SE can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Valneva SE's financial leverage. It provides some insight into what part of Valneva SE's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Valneva SE ADR (VALN) is traded on NASDAQ Exchange in USA and employs 676 people. Valneva SE is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 352.47 M. Valneva SE ADR conducts business under Biotechnology sector and is part of Health Care industry. The entity has 81.2 M outstanding shares of which 15.89 K shares are at this time shorted by private and institutional investors with about 0.24 trading days to cover.
Valneva SE ADR currently holds about 336.22 M in cash with (202.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Valneva SE Probability Of Bankruptcy
Ownership AllocationValneva SE ADR shows a total of 81.2 Million outstanding shares. About 98.84 % of Valneva SE outstanding shares are held by general public with 1.16 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Valneva Ownership Details
Valneva Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 0.0 | |
| Ubs Group Ag | 2024-06-30 | 0.0 | |
| Qube Research & Technologies | 2024-09-30 | 0.0 | |
| General American Investors Co Inc | 2024-09-30 | 354.4 K | |
| Wells Fargo & Co | 2024-09-30 | 215.9 K | |
| Alphacentric Advisors, Llc | 2024-09-30 | 118 K | |
| Ironwood Investment Management Llc | 2024-09-30 | 25 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 3.6 K | |
| Ridgewood Investments Llc | 2024-09-30 | 550 | |
| Alphamark Advisors, Llc | 2024-09-30 | 150 | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 150 |
Valneva SE Historical Income Statement
Valneva Stock Against Markets
Valneva SE Corporate Management
| Vincent Dequenne | Chief Officer | Profile | |
| Frederic Jacotot | General IP | Profile | |
| JuanCarlos MD | Chief Officer | Profile | |
| Gerald Strohmaier | VP Resource | Profile | |
| Peter Buhler | Chief Officer | Profile | |
| Christian Taucher | Head Affairs | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Valneva SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Valneva SE. If investors know Valneva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Valneva SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.204 | Return On Assets | Return On Equity |
The market value of Valneva SE ADR is measured differently than its book value, which is the value of Valneva that is recorded on the company's balance sheet. Investors also form their own opinion of Valneva SE's value that differs from its market value or its book value, called intrinsic value, which is Valneva SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Valneva SE's market value can be influenced by many factors that don't directly affect Valneva SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Valneva SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Valneva SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Valneva SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.